Core One Labs Inc. (CLABF)
OTCMKTS
· Delayed Price · Currency is USD
0.0406
-0.0219 (-35.04%)
Apr 29, 2025, 2:12 PM EDT
Core One Labs Revenue
In the fiscal year ending March 31, 2023, Core One Labs had annual revenue of 458.54K CAD, down -29.25%. Core One Labs had revenue of 93.66K in the quarter ending December 31, 2023, a decrease of -17.22%.
Revenue
458.54K CAD
Revenue Growth
-18.65%
P/S Ratio
14.68
Revenue / Employee
n/a
Employees
n/a
Market Cap
4.97M USD
Revenue Chart
* This company reports financials in CAD.
Revenue History
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Endo Inc. | 1.76B |
Veradigm | 588.02M |
Glass House Brands | 200.90M |
Elite Pharmaceuticals | 70.00M |
Northwest Biotherapeutics | 1.38M |
BioStem Technologies | 301.83M |
American Oncology Network | 1.76B |
Silence Therapeutics | 43.26M |
Core One Labs News
- 10 months ago - Core One Enters into Loan Agreement with Right Season Investments - Accesswire
- 1 year ago - Core One Labs Inc. Announces Initial Agreement for Potential Sale of Proprietary Biosynthetic Psilocybin, Facilitating Entry into the International Market - Accesswire
- 1 year ago - Core One Labs' Akome Reveals Impressive Results for its Psychedelic Bio-Compounds Designed to Target Alzheimer's and Parkinson's, Showing Potential to Outperform Current Treatment Methods - Accesswire
- 1 year ago - Core One's Akome Reveals Groundbreaking Positive Results from its Second Round of Stage 1 Animal Model Studies for Bio-Compounds Targeting Alzheimer's and Parkinson's Disease - Accesswire
- 1 year ago - Core One Labs', Awakened Biosciences, Announces Groundbreaking Step Forward in Isolating and Purifying Psilocybin from Mushroom Biomass - Accesswire
- 1 year ago - Core One's Akome Receives Positive Preliminary Stage 1 Animal Model Study Results for Bio-Compound Targeting Alzheimer's and Parkinson's Disease - Accesswire
- 1 year ago - Core One Labs Enters into Letter of Intent for First Sale of Its Psychedelic Compounds - Accesswire
- 1 year ago - Core One's Vocan Biotechnologies Incorporates New Bioreactor Equipment into Production Process Significantly Increasing Throughput of Proprietary Biosynthetic Psilocybin - Accesswire